Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 0.50 |
| ▸ | RAF1 | P04049 | 14/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716871 | 0.91 | BRAF (0.51) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL4883082 | 0.91 | RAF1 (0.47) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL14164073 | 0.86 | RAF1 (0.50) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL4907627 | 0.84 | MEN1 (0.56) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL14164130 | 0.82 | RAF1 (0.49) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL4717419 | 0.81 | BRAF (0.51) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL4718886 | 0.80 | RAF1 (0.50) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL4883306 | 0.79 | MEN1 (0.57) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL4716313 | 0.77 | KMT2A (0.60) | BRAFRAF1MEN1NPC1RAB9A | |
| SCHEMBL4716331 | 0.77 | MEN1 (0.60) | BRAFRAF1MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1848715-A1 | COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006082404-A1 | COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | TEK, TIE1, KDR | BRAF 2750/4885RAF1 2106/4885MEN1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.